<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bourlière, Marc</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">The once-daily, oral, 12-week regimen using a single tablet combination of sofosbuvir (SOF; 400 mg) and ledipasvir (LDV; 90 mg) with or without ribavirin produces high sustained virologic response 12 weeks after conclusion of treatment in hepatitis C virus (HCV)-infected patients with compensated cirrhosis. This article discussed a study comprised of pooled data from the LONESTAR, ELECTRON and ELECTRON-2, ION-1 and ION-2, and SIRIUS trials.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>